Solventum Corporation $SOLV Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC raised its position in Solventum Corporation (NYSE:SOLV) by 8.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,662 shares of the company’s stock after buying an additional 356 shares during the period. Motley Fool Asset Management LLC’s holdings in Solventum were worth $354,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Chelsea Counsel Co. boosted its holdings in Solventum by 720.7% in the 2nd quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock worth $804,000 after buying an additional 9,304 shares during the last quarter. ST Germain D J Co. Inc. boosted its holdings in Solventum by 84.6% in the 2nd quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock worth $63,000 after buying an additional 378 shares during the last quarter. CX Institutional boosted its holdings in Solventum by 11.7% in the 2nd quarter. CX Institutional now owns 2,376 shares of the company’s stock worth $180,000 after buying an additional 249 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in Solventum in the 2nd quarter worth about $71,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in Solventum by 0.9% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock worth $4,832,000 after buying an additional 583 shares during the last quarter.

Analysts Set New Price Targets

Several research firms recently issued reports on SOLV. Piper Sandler reiterated an “overweight” rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a report on Friday, August 8th. UBS Group started coverage on Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a report on Wednesday, October 8th. Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Finally, Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $84.89.

Solventum Stock Down 1.3%

SOLV stock opened at $71.04 on Wednesday. The firm has a market cap of $12.32 billion, a PE ratio of 32.89, a PEG ratio of 2.92 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The firm’s 50 day moving average price is $72.62 and its 200-day moving average price is $72.28. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, beating the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.